Ovid Therapeutics Inc.
OVID· Nasdaq
Released May 5, 2023, before the open
10-Q filed May 5, 2023, 35 days after period end · 0001628280-23-016013
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $66.00K | $1.45M | $208.38M | — |
| Net Income | -$13.36M | -$16.11M | $176.01M | -$20.03M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.19 |
| -$0.23 |
| $2.53 |
| -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.